Novartis sues Lupin, Torrent over ANDAs filed for generic Exforge HCT

Novartis has sued Lupin and Torrent Pharmaceuticals in district court regarding the filing of ANDAs with the US FDA, as the generics firms seek to bring to market their versions of the antihypertensive Exforge HCT (a combination of valsartan, amlodipine and hydrochlorothiazide) before patent expiry of US patents covering the product.

Novartis has sued Lupin and Torrent Pharmaceuticals in district court regarding the filing of ANDAs with the US FDA, as the generics firms seek to bring to market their versions of the antihypertensive Exforge HCT (a combination of valsartan, amlodipine and hydrochlorothiazide) before patent expiry of US patents covering the product.

Exforge HCT received US approval in 2009 and was launched that year, as the first triple combination product for hypertension.

More from Cardiovascular

Mineralys Eyes NDA As Lorundrostat Scores CKD Win In Race With AstraZeneca

 

As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.

Merck & Co.’s Winrevair Positioned For Expansion On HYPERION Results

 

The Phase III trial met the primary endpoint of time to clinical worsening in patients newly diagnosed with pulmonary arterial hypertension.

Obesity Treatment Could Go Global With Lilly’s Orforglipron

 

The company’s oral GLP-1 candidate has reassured on its safety at the American Diabetes Association meeting, convincing analysts it will open up new global markets.

Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve

 
• By 

Instead of opting in on Phase II-ready PCSK9-targeted VERVE-102, Lilly will buy its partner for up to $1.3bn. Analysts call the deal a bargain for Lilly, but fair to Verve.

More from Therapeutic Category

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By 

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.